| afatinib based treatment | neratinib based treatment | pertuzumab based treatment | trastuzumab based treatment | tucatinib based treatment | lapatinib based treatment |
| afatinib plus vinorelbine | neratinib | neratinib plus capecitabine | pertuzumab plus trastuzumab | pertuzumab plus trastuzumab plus docetaxel | trastuzumab plus endocrine therapy | trastuzumab plus epirubicin and cyclophosphamide followed by docetaxel | tucatinib plus trastuzumab plus capecitabine | lapatinib | lapatinib plus capecitabine | lapatinib plus trastuzumab |
es-BC - HER2 negative - (neo)adjuvant (NA) 1 | | | | | | | | | | | |
es-BC - HER2 positive - (neo)adjuvant (NA) 4 | | | | | | | | | | | |
la/mBC - HER2 positive | | | | | | | | | | | |
la/mBC - HER2 positive - (neo)adjuvant (NA) | | | | | | | | | | | |
la/mBC - HER2 positive - 1st Line (L1) 5 | | | | | | | | | | | |
la/mBC - HER2 positive - 2nd Line (L2) 13 | | | | | | | | | | | |